Baxter International BAX Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Arthur J. GallagherAJG

$11M—

BorgWarnerBWA

$2.11B+23.6%

BKBK

$4.4B+15.8%

Arthur J. GallagherAJG

$1.17B-92.9%

InsuletPODD

$480.4M-62.6%

GE HealthCare TechnologiesGEHC

$2.29B-7.6%

Other financials

Income statement

See full

Revenue$2.7B+2.9%

Gross profit$891.0M+3.5%

Operating income$66.0M+13.8%

Net income-$15.0M-112%

EPS (diluted)-$0.03-112%

Balance sheet

See full

Cash & equivalents$2.0B-12.1%

Total debt$224.0M-8.9%

Total equity$6.0B-14.7%

Total assets$19.8B-6.8%

Cash flow

See full

Operating cash flow$213.0M+210%

CapEx$128.3M+15.0%

Free cash flow$83.0M-42.1%

Valuation

See full

Market cap$10.27B-50.6%

Enterprise value$8.48B-55.6%

P/S0.9×-1.0×

Profitability

See full

Gross margin30.1%-5.9pp

Operating margin-2.7%—

Net margin-9.7%+62.5pp

FCF margin3%-2.4pp

Returns & leverage

See full

Return on equity-16.7%-76.7pp

Debt / equity0×0.0×

Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Baxter International's cash, cash equivalents, and marketable securities?: Baxter International (BAX) reported cash, cash equivalents, and marketable securities of $1M in Q1 2026.